Evidence Hub

Use of phosphodiesterase type 5 inhibitors in assistive living and home care settings

Iannino-Renz R, Mager D

Applied nursing research : ANR, 2015

126 participants

Abstract

UNLABELLED: The purpose of this descriptive study was to assess frequency of phosphodiesterase type (PDE-5) inhibitor use (sildenafil, tadalafil, ardenafil) in community settings.

METHODS: A retrospective record review was conducted to determine PDE-5 inhibitor use in older males (mean age 79.2) residing in three assisted living communities (n=126), or living in private homes with home care services (n=109).

RESULTS: Two participants from assisted living had PDE-5 inhibitors listed on medication profiles, while no participants from the home care setting had any listed.

IMPLICATIONS: Many factors may have contributed to the absence of PDE-5 inhibitors in records, including comorbidities precluding use; fear of side effects; reluctance to report use; and lack of erectile dysfunction diagnosis to name a few. It is unknown whether sexual function, or the need for PDE-5 inhibitors was ever assessed by providers. Future research is warranted given the aging population and the benefits of holistic assessments.

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 126 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free